Trihexyphenidyl treatment of clozapine-induced hypersalivation

Int Clin Psychopharmacol. 1997 Jul;12(4):213-5. doi: 10.1097/00004850-199707000-00005.


The objective of this study was to investigate the efficacy of the anticholinergic agent trihexyphenidyl in the treatment of clozapine-induced hypersalivation. Fourteen chronic schizophrenic patients who exhibited nocturnal hypersalivation during clozapine treatment were coadministered trihexyphenidyl (5-15 mg/day, at bedtime) for 15 days. Salivation was assessed by a single-item 5-point scale. A reduction of 44% in the reported nocturnal hypersalivation was observed after trihexyphenidyl treatment. These results indicate that at least some chronic schizophrenic patients with clozapine-induced nocturnal hypersalivation may benefit from anticholinergic treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Clozapine / adverse effects*
  • Female
  • Humans
  • Male
  • Muscarinic Antagonists / therapeutic use*
  • Schizophrenia / drug therapy
  • Sialorrhea / chemically induced*
  • Sialorrhea / drug therapy*
  • Trihexyphenidyl / therapeutic use*


  • Antipsychotic Agents
  • Muscarinic Antagonists
  • Trihexyphenidyl
  • Clozapine